InvestorsHub Logo
Followers 4
Posts 1195
Boards Moderated 0
Alias Born 10/03/2015

Re: None

Thursday, 03/24/2016 12:45:16 PM

Thursday, March 24, 2016 12:45:16 PM

Post# of 977
75 millions for combo studies after seeing P1 data. Would someone pay that much if the mAB is not safe? Not good news for bi-specific.


Forty Seven will use the proceeds of the Series A financing to complete the two ongoing clinical studies, fund additional clinical trials in 2016 to assess Hu5F9-G4 in combination therapy .........